With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients

Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.

Kidneys
• Source: Shutterstock

The latest label expansion for Novartis’s Fabhalta (iptacopan), for C3 glomerulopathy (C3G), allows the firm to expand its growing presence in the renal disease space, which the Swiss drug maker will do by employing digital technology and artificial intelligence to reach patients with the rare kidney disease.

The US Food and Drug Administration approved Fabhalta, a complement factor B inhibitor, on 20 March for reducing proteinuria in...

Welcome to Scrip

Create an account to read this article

More from New Products

Insmed Targets $5bn-Plus Market With Brinsupri For Bronchiectasis

 
• By 

The US FDA approved Insmed’s second product, the DPP1 inhibitor Brinsupri (brensocatib) for non-cystic fibrosis bronchiectasis. The company launched the drug immediately with a list price of $88,000 per year.

Boehringer Scores First Approval For Targeted Oral Drug In HER2-Mutant NSCLC

 

The US FDA approved Hernexeos for previously treated HER2-mutant NSCLC, making it the first oral option in a setting where drugs like AstraZeneca/Daiichi Sankyo’s Enhertu dominate.

Pipeline Watch: Five Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

PTC Projects Confidence In Sephience Launch With Royalty Buyback

 
• By 

The company will start shipping its newly launched phenylketonuria drug within two weeks and has bought back global net sales obligations for the treatment.

More from Digital Technologies

Beyond AI Hype: Tokyo-1’s Real Answer On How To Innovate Pharma R&D

 
• By 

Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.

Decentralized Trials Enroll Larger, More Diverse Patient Populations

 

A new study by Tufts CSDD performed a deep dive into use of decentralized clinical trial techniques, but one of the study’s authors said DCTs have been dialed back.

Sanofi Links Up Again With Formation To Take Gusacitinib Down New Path

 
• By 

Deal Snapshot: The Paris-headquartered company has licensed gusacitinib, which was in development for chronic hand eczema, but Sanofi will pursue a new indication for the dual JAK/SYK inhibitor.